Plasmatická hladina transformujícího růstového faktoru beta 1 (TGF-beta 1) predikuje pozdní morbiditu u pacientů s pokročilými tumory hlavy a krku
Tvůrce(i)
Feltl, D. (CZ) Závadová, E. (CZ) Pála, M. (CZ) Hozák, Pavel (UEM-P)
Zdroj.dok.
Neoplasma
- ISSN 0028-2685
Roč. 52, č. 5 (2005), s. 393-397
Poč.str.
5 s.
Jazyk dok.
eng - angličtina
Země vyd.
SK - Slovensko
Klíč. slova
head and neck cancer ; late morbidity
Vědní obor RIV
EE - Mikrobiologie, virologie
CEP
IAA5039202 GA AV ČR - Akademie věd
CEZ
AV0Z50390512 - UEM-P (2005-2011)
Anotace
29 patients with advanced inoperable squamous head and neck cancer treated with radiotherapy with or without simultaneous chemotherapy were evaluated for their plasma TGF-beta1 levels prior to the treatment, in the middle of the radiotherapy course and at the end of the treatment. Neither pre-treatment nor post-treatment plasma TGF-beta1 level has a predictive value to the treatment response. The post-treatment plasma TGF-beta 1 level can predict late morbidity grade >1 in advanced head and neck cancor treated with radio(chemo)therapy. This could make a basis for dose escalation in selected patients.
